Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use

Gender Medicine

Volumn 9, Issue 2, 2012, Pages 112-120

  Heinzerling, Keith G ^a   Shoptaw, Steven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BDNF Val66Met; brain derived neurotrophic factor; gender; methamphetamine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; METHAMPHETAMINE;

ADULT; ARTICLE; CAUCASIAN; CLINICAL TRIAL (TOPIC); DRUG DEPENDENCE; DRUG USE; EXPLORATORY RESEARCH; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SCREENING; SEX DIFFERENCE;

AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MALE; METHAMPHETAMINE; POLYMORPHISM, GENETIC; SEX FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84859523323     PISSN: 15508579     EISSN: 18787398     Source Type: Journal    
DOI: 10.1016/j.genm.2012.02.005     Document Type: Article

References (50)

1. Hillhouse MP, Marinelli-Casey P, Gonzales R, et al. Predicting in-treatment performance and posttreatment outcomes in methamphetamine users. Addiction. 2007;102(Suppl 1):84-95. (Pubitemid 46328206)
2. Elkashef AM, Rawson RA, Anderson AL, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology. 2008;33: 1162-1170. (Pubitemid 351367539)
3. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008; 96:222-232.
4. Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gend Med. 2008;5:24-35. (Pubitemid 351506544)
5. Evans SM, Foltin RW. Does the response to cocaine differ as a function of sex or hormonal status in human and non-human primates? Horm Behav. 2010;58:13-21.
6. Roth ME, Carroll ME. Sex differences in the acquisition of IV methamphetamine self-administration and subsequent maintenance under a progressive ratio schedule in rats. Psychopharmacology (Berl). 2004;172:443-449. (Pubitemid 38650981)
7. Dluzen DE, Salvaterra TJ. Sex differences in methamphetamine- evoked striatal dopamine output are abolished following gonadectomy: comparisons with potassium-evoked output and responses in prepubertal mice. Neuroendocrinology. 2005;82:78-86.
8. Myers RE, Anderson LI, Dluzen DE. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology. 2003;44:624-632. (Pubitemid 36369142)
9. Dluzen DE, McDermott JL. Sex differences in dopamine- and vesicular monoamine-transporter functions. Ann N Y Acad Sci. 2008;1139: 140 -150.
10. Wagner GC, Tekirian TL, Cheo CT. Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm Gen Sect. 1993;93:67-70. (Pubitemid 23235619)
11. Lewis C, Dluzen DE. Testosterone enhances dopamine depletion by methamphetamine in male, but not female, mice. Neurosci Lett. 2008; 448:130-133.
12. Gajjar TM, Anderson LI, Dluzen DE. Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm. 2003;110:1215-1224. (Pubitemid 37500744)
13. Dluzen DE, McDermott JL. Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system. Ann N Y Acad Sci. 2000;914: 112-126.
14. Munro CA, McCaul ME, Wong DF, et al. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006;59:966-974.
15. Riccardi P, Zald D, Li R, et al. Sex differences in amphetamine-induced displacement of [(18)F]fallypride in striatal and extrastriatal regions: a PET study. Am J Psychiatry. 2006;163:1639-1641. (Pubitemid 44465768)
16. Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867-869. (Pubitemid 30456771)
17. Mozley LH, Gur RC, Mozley PD, Gur RE. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry. 2001; 158:1492-1499. (Pubitemid 32847251)
18. Staley JK, Krishnan-Sarin S, Zoghbi S, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse. 2001; 41:275-284. (Pubitemid 32702249)
19. White TL, Justice AJ, de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002;73:729-741. (Pubitemid 35251831)
20. Vansickel AR, Lile JA, Stoops WW, Rush CR. Similar discriminative- stimulus effects of D-amphetamine in women and men. Pharmacol Biochem Behav. 2007;87:289-296. (Pubitemid 46963362)
21. Justice AJ, de Wit H. Acute effects of estradiol pretreatment on the response to d-amphetamine in women. Neuroendocrinology. 2000;71: 51-59. (Pubitemid 30045335)
22. Lile JA, Kendall SL, Babalonis S, et al. Evaluation of estradiol administration on the discriminativestimulus and subject-rated effects of d-amphetamine in healthy pre-menopausal women. Pharmacol Biochem Behav. 2007;87:258-266. (Pubitemid 46963359)
23. Reed SC, Levin FR, Evans SM. The effects of progesterone pretreatment on the response to oral d-amphetamine in women. Horm Behav. 2010;58: 533-543.
24. Holdcraft LC, Iacono WG. Cross-generational effects on gender differences in psychoactive drug abuse and dependence. Drug Alcohol Depend. 2004;74:147-158. (Pubitemid 38501688)
25. Vansickel AR, Stoops WW, Rush CR. Human sex differences in d-amphetamine self-administration. Addiction. 2010;105:727-731.
26. Gabbay FH. Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol. 2003; 11:91-101. (Pubitemid 36237346)
27. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci (Lond). 2006; 110:167-173. (Pubitemid 43241478)
28. Narita M, Aoki K, Takagi M, et al. Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine. Neuroscience. 2003; 119:767-775. (Pubitemid 36694803)
29. Saylor AJ, McGinty JF. Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice. Genes Brain Behav. 2008;7:906-914.
30. Thomas DM, Francescutti-Verbeem DM, Liu X, Kuhn DM. Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment - an oligonucleotide microarray approach. J Neurochem. 2004;88:380-393. (Pubitemid 38084554)
31. Grace CE, Schaefer TL, Herring NR, et al. (+)-Methamphetamine increases corticosterone in plasma and BDNF in brain more than forced swim or isolation in neonatal rats. Synapse. 2008;62:110-121.
32. Kim DJ, Roh S, Kim Y, et al. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett. 2005;388: 112-115. (Pubitemid 41206742)
33. Hilburn C, Nejtek VA, Underwood WA, et al. Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine? Neuropsychiatr Dis Treat. 2011;7: 357-364.
34. Matsuzaki H, Namikawa K, Kiyama H, et al. Brain-derived neurotrophic factor rescues neuronal death induced by methamphetamine. Biol Psychiatry. 2004;55:52-60. (Pubitemid 38045433)
35. Dluzen DE, McDermott JL. Developmental and genetic influences upon gender differences in methamphetamine- induced nigrostriatal dopaminergic neurotoxicity. Ann N Y Acad Sci. 2004;1025:205-220. (Pubitemid 39643864)
36. Cass WA, Peters LE, Harned ME, Seroogy KB. Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci. 2006;1074:272-281. (Pubitemid 44532830)
37. Chen ZY, Patel PD, Sant G, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci. 2004; 24:4401- 4411.
38. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257-269. (Pubitemid 36144114)
39. Cheng CY, Hong CJ, Yu YW, et al. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res. 2005;140:86-90. (Pubitemid 41446150)
40. Sim MS, Mohamed Z, Hatim A, et al. Association of brain-derived neurotrophic factor (Val66Met) genetic polymorphism with methamphetamine dependence in a Malaysian population. Brain Res. 2010;1357:91-96.
41. Bousman CA, Glatt SJ, Cherner M, et al. Preliminary evidence of ethnic divergence in associations of putative genetic variants for methamphetamine dependence. Psychiatry Res. 2010; 178:295-298.
42. Itoh K, Hashimoto K, Shimizu E, et al. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet. 2005;132:70-73. (Pubitemid 40066199)
43. Flanagin BA, Cook EH Jr, de Wit H. An association study of the brain-derived neurotrophic factor Val66Met polymorphism and amphetamine response. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:576-583. (Pubitemid 44434657)
44. Heinzerling KG, McCracken JT, Swanson AN, et al. COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol. 2012;32: 135-137.
45. Sohrabji F, Miranda RC, Toran-Allerand CD. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci U S A. 1995;92:11110-11114.
46. Sohrabji F, Lewis DK. Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol. 2006;27:404-414. (Pubitemid 44738016)
47. Ivanova T, Kuppers E, Engele J, Beyer C. Estrogen stimulates brain-derived neurotrophic factor expression in embryonic mouse midbrain neurons through a membrane-mediated and calcium-dependent mechanism. J Neurosci Res. 2001;66:221-230. (Pubitemid 32912291)
48. Kuppers E, Krust A, Chambon P, Beyer C. Functional alterations of the nigrostriatal dopamine system in estrogen receptor-alpha knockout (ERKO) mice. Psychoneuroendocrinology. 2008; 33:832-838.
49. Heinzerling KG, Swanson AN, Kim S, et al. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2010; 109:20-29.
50. Milesi-Halle A, Hendrickson HP, Laurenzana EM, et al. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol Appl Pharmacol. 2005;209:203-213. (Pubitemid 41713945)